{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:04:01Z","timestamp":1790420641697,"version":"4.1.0"},"reference-count":223,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.phrs.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:10:26Z","timestamp":1552446626000},"page":"19-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":474,"special_numbering":"C","title":["Properties of FDA-approved small molecule protein kinase inhibitors"],"prefix":"10.1016","volume":"144","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.phrs.2019.03.006_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2019.03.006_bib0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.03.006_bib0030","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.03.006_bib0040","first-page":"345","article-title":"Glaucoma drugs in the pipeline","volume":"7","author":"Kaufman","year":"2018","journal-title":"Asia Pac. J. Ophthalmol. (Phila.)"},{"key":"10.1016\/j.phrs.2019.03.006_bib0045","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.03.006_bib0050","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.03.006_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0060","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0065","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"58","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0070","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Ann. Rep. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0080","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2019.03.006_bib0085","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pro.5560030203","article-title":"cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer","volume":"3","author":"Madhusudan","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0090","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2019.03.006_bib0095","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the conserved internal architecture of a protein kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2019.03.006_bib0105","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.chembiol.2013.05.005","article-title":"Sequence determinants of a specific inactive protein kinase conformation","volume":"20","author":"Hari","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0110","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.03.006_bib0115","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.03.006_bib0120","doi-asserted-by":"crossref","first-page":"e1001690","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0145","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0160","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0175","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0180","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0215","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0220","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0225","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0235","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2019.03.006_bib0245","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2019.03.006_bib0250","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.bioconjchem.6b00243","article-title":"Bivalent inhibitors of c-Src tyrosine kinase that bind a regulatory domain","volume":"27","author":"Johnson","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0255","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0260","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nrd.2015.18","article-title":"The drug-target residence time model: a 10-year retrospective","volume":"15","author":"Copeland","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.03.006_bib0270","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0275","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0280","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0285","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/acs.chemrev.5b00484","article-title":"The halogen bond","volume":"116","author":"Cavallo","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0290","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-91442-8_4","article-title":"Crizotinib","volume":"211","author":"Heigener","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0300","first-page":"72","article-title":"ALK and ROS1 as a joint target for the treatment of lung cancer: a review","volume":"2","author":"Puig de la Bellacasa","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0305","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10245332.2017.1385193","article-title":"Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature","volume":"23","author":"Ongoren","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.phrs.2019.03.006_bib0315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0320","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0325","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0330","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0335","first-page":"189","article-title":"Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"9","author":"Kucharczuk","year":"2018","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0340","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-019-05133-y","article-title":"Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials","author":"Petrelli","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2019.03.006_bib0345","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918793849","article-title":"Updates on managing advanced breast cancer with palbociclib combination therapy","volume":"10","author":"McShane","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0350","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0355","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0360","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737140.2016.1238764","article-title":"The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer","volume":"16","author":"Fallahi","year":"2016","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0365","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","article-title":"Advanced stage melanoma therapies: detailing the present and exploring the future","volume":"133","author":"Luther","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0370","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","article-title":"Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET","volume":"211","author":"Zsch\u00e4bitz","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0385","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-3-319-91442-8_6","article-title":"Vemurafenib","volume":"211","author":"Garbe","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0395","first-page":"2777","article-title":"Erdheim-Chester disease: comprehensive review of molecular profiling and therapeutic advances","volume":"37","author":"Haroun","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0400","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-017-0840-z","article-title":"Abemaciclib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0405","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.2147\/OTT.S149245","article-title":"Profile of abemaciclib and its potential in the treatment of breast cancer","volume":"11","author":"Martin","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0410","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0415","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918776925","article-title":"The role of abemaciclib in treatment of advanced breast cancer","volume":"10","author":"McCartney","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0420","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-3-319-91442-8_17","article-title":"Alectinib","volume":"211","author":"Herden","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0425","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0430","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918789364","article-title":"Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy","volume":"10","author":"Vaval\u00e0","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0435","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.2217\/fon-2018-0027","article-title":"The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"14","author":"Gadgeel","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0440","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","article-title":"Ceritinib: first global approval","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0445","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.006_bib0450","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2217\/fon-2017-0262","article-title":"Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib","volume":"13","author":"De Pas","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0455","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.2147\/CMAR.S173084","article-title":"Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer","volume":"10","author":"Mohieldin","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0460","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1186\/s12885-018-5078-y","article-title":"Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2019.03.006_bib0465","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0470","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40265-017-0742-0","article-title":"Ribociclib: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0475","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0480","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10549-017-4523-y","article-title":"Ribociclib with letrozole versus letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial","volume":"167","author":"Sonke","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2019.03.006_bib0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10549-017-4518-8","article-title":"Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2 \u2013 advanced breast cancer in the randomized MONALEESA-2 trial","volume":"168","author":"O'Shaughnessy","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2019.03.006_bib0490","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-319-91442-8_11","article-title":"Palbociclib-the first of a new class of cell cycle inhibitors","volume":"211","author":"Schmidt","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0495","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-91442-8_1","article-title":"Erlotinib","volume":"211","author":"Steins","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0505","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017753338","article-title":"Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","volume":"10","author":"Hirsh","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0510","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2019.03.006_bib0515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","article-title":"Lapatinib","volume":"211","author":"Voigtlaender","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5414\/CP203123","article-title":"Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: a systematic review","volume":"56","author":"Madden","year":"2018","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0525","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.2147\/DDDT.S109640","article-title":"Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy","volume":"11","author":"Bellesoeur","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0530","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","article-title":"Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial","volume":"15","author":"Hutson","year":"2017","journal-title":"Clin. Genitourin Cancer"},{"key":"10.1016\/j.phrs.2019.03.006_bib0535","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0540","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2019.03.006_bib0545","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0550","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel","volume":"120","author":"M\u00fcller","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0555","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2019.03.006_bib0560","doi-asserted-by":"crossref","first-page":"e13779","DOI":"10.1097\/MD.0000000000013779","article-title":"A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.phrs.2019.03.006_bib0565","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.18632\/oncotarget.14671","article-title":"Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2019.03.006_bib0570","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.critrevonc.2016.01.014","article-title":"Is there still a role for sorafenib in metastatic renal cell carcinoma?. A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents","volume":"99","author":"Iacovelli","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0575","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0580","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-015-0477-8","article-title":"Cobimetinib: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0585","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1060028016672037","article-title":"Cobimetinib","volume":"51","author":"Signorelli","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2019.03.006_bib0590","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40265-016-0562-7","article-title":"Cobimetinib plus vemurafenib: a review in BRAFV600 mutation-positive unresectable or metastatic melanoma","volume":"76","author":"Keating","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0595","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0600","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2019.03.006_bib0605","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-319-91442-8_14","article-title":"Afatinib","volume":"211","author":"Wecker","year":"2018","journal-title":"Recent Results Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2019.03.006_bib0610","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3747\/co.25.3732","article-title":"Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0615","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2019.03.006_bib0620","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.hoc.2018.05.014","article-title":"Novel approaches in Waldenstr\u00f6m macroglobulinemia","volume":"32","author":"Spinner","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.phrs.2019.03.006_bib0625","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.mayocp.2018.03.002","article-title":"Chronic lymphocytic leukemia: diagnosis and treatment","volume":"93","author":"Strati","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.phrs.2019.03.006_bib0630","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phrs.2019.03.006_bib0635","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0640","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0645","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0650","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtho.2018.01.009","article-title":"EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib","volume":"13","author":"Kobayashi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0655","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-015-0533-4","article-title":"Osimertinib: first global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0660","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-319-91442-8_18","article-title":"Osimertinib","volume":"211","author":"Malapelle","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0665","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0670","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.2012.43.0652","article-title":"Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?","volume":"31","author":"Mok","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0675","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0680","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/jm040159c","article-title":"Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity","volume":"48","author":"Tsou","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0685","first-page":"2183","article-title":"Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs","volume":"16","author":"Jiang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0690","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and Drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0695","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1756287215614236","article-title":"Pazopanib in the treatment of advanced renal cell carcinoma","volume":"8","author":"Cella","year":"2016","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0700","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0705","first-page":"20","article-title":"Therapeutic targets for bone and soft-tissue sarcomas","author":"Miwa","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0710","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0715","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0720","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0725","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.006_bib0730","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","author":"Ettrich","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0735","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.011","article-title":"Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review","volume":"62","author":"R\u00f8ed Sk\u00e5rderud","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0740","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2016.11.011","article-title":"GEIS guidelines for gastrointestinal sarcomas (GIST)","volume":"55","author":"Poveda","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0745","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.006_bib0750","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2019.03.006_bib0755","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-319-91442-8_7","article-title":"Trametinib (GSK1120212)","volume":"211","author":"Zeiser","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0760","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0765","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0770","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.2147\/OTT.S171693","article-title":"Encorafenib\/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy","volume":"11","author":"Sun","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0775","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.09.001","article-title":"Recently approved therapies in acute myeloid leukemia: a complex treatment landscape","volume":"73","author":"Talati","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0780","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","article-title":"Comparison of the kinase profile of midostaurin (Rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to leukemia therapy","volume":"57","author":"Manley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2019.03.006_bib0785","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1060028017747900","article-title":"Midostaurin in combination with standard chemotherapy for treatment of newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukemia","volume":"52","author":"Kim","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.phrs.2019.03.006_bib0790","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation","volume":"377","author":"D\u00f6hner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0795","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOH.0000000000000490","article-title":"Progress in the problem of relapsed or refractory acute myeloid leukemia","volume":"26","author":"Mims","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0800","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0805","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","article-title":"Acalabrutinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0810","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0815","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0820","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.006_bib0825","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40265-018-1041-0","article-title":"Lorlatinib: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0830","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejmech.2017.04.032","article-title":"First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK\/ROS1 cancer: clinical and designing strategy update of lorlatinib","volume":"134","author":"Basit","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib0835","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0840","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0845","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/phar.2076","article-title":"Cabozantinib: a multitargeted oral tyrosine kinase inhibitor","volume":"38","author":"Markowitz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2019.03.006_bib0850","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-017-0566-9","article-title":"Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma","volume":"19","author":"Tannir","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.phrs.2019.03.006_bib0855","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-16-1073","article-title":"U.S. food and drug administration approval: cabozantinib for the treatment of advanced renal cell carcinoma","volume":"23","author":"Singh","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0860","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-018-0109-6","article-title":"Emerging therapies in advanced hepatocellular carcinoma","volume":"7","author":"Medavaram","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0865","article-title":"Larotrectinib: first global approval","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0870","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0875","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2019.03.006_bib0880","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib0885","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00003495-200767030-00004","article-title":"Use of sirolimus in solid organ transplantation","volume":"67","author":"Augustine","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0890","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ahj.2017.08.001","article-title":"Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach","volume":"193","author":"Doros","year":"2017","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2019.03.006_bib0895","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccm.2016.04.002","article-title":"Lymphangioleiomyomatosis","volume":"37","author":"Johnson","year":"2016","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0900","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0905","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0910","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ctrv.2018.07.013","article-title":"Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer","volume":"69","author":"O'Shaughnessy","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib0915","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.03.006_bib0920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CE.S98687","article-title":"Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy","volume":"11","author":"Buti","year":"2016","journal-title":"Core Evid."},{"key":"10.1016\/j.phrs.2019.03.006_bib0925","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/CMAR.S113382","article-title":"Emerging use of everolimus in the treatment of neuroendocrine tumors","volume":"9","author":"Gajate","year":"2017","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0930","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.pcl.2015.03.005","article-title":"Tuberous sclerosis complex","volume":"62","author":"DiMario","year":"2015","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/j.phrs.2019.03.006_bib0935","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nyas.12122","article-title":"Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases","volume":"1291","author":"Lebwohl","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib0940","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737140.2014.864562","article-title":"Temsirolimus for advanced renal cell carcinoma","volume":"14","author":"Bergmann","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib0945","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2019.03.006_bib0950","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0955","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0960","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-3-319-91439-8_6","article-title":"Ruxolitinib","volume":"212","author":"Ajayi","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib0965","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","article-title":"Ruxolitinib: a review of its use in patients with myelofibrosis","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0970","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0975","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40268-017-0221-9","article-title":"Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: an update","volume":"18","author":"Rodr\u00edguez-Portal","year":"2018","journal-title":"Drugs R. D."},{"key":"10.1016\/j.phrs.2019.03.006_bib0980","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.03.006_bib0985","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14423\/SMJ.0000000000000655","article-title":"Pirfenidone and nintedanib for treatment of idiopathic pulmonary fibrosis","volume":"110","author":"Sathiyamoorthy","year":"2017","journal-title":"South Med. J."},{"key":"10.1016\/j.phrs.2019.03.006_bib0990","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-018-0877-7","article-title":"Netarsudil ophthalmic solution 0.02%: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib0995","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acs.jmedchem.5b00828","article-title":"Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions","volume":"59","author":"Donegan","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib1000","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/jop.2017.0023","article-title":"Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma","volume":"34","author":"Lin","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.03.006_bib1005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib1010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2019.03.006_bib1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6468(09)04801-2","article-title":"Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design","volume":"48","author":"Smith","year":"2009","journal-title":"Prog. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib1020","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.03.006_bib1025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","article-title":"Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions","volume":"101","author":"Lipinski","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib1030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11095-015-1779-y","article-title":"Thermodynamic proxies to compensate for biases in drug discovery methods","volume":"33","author":"Ekins","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib1035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.03.006_bib1040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2019.03.006_bib1045","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib1050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2019.03.006_bib1055","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2019.03.006_bib1060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Compout. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib1065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/cb300610s","article-title":"Kinase drug discovery--what's next in the field?","volume":"8","author":"Cohen","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2019.03.006_bib1070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.tips.2005.12.002","article-title":"Targeting Rho and Rho-kinase in the treatment of cardiovascular disease","volume":"27","author":"Budzyn","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2019.03.006_bib1075","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/jm9012906","article-title":"Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders","volume":"53","author":"Goldstein","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib1080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The jakinibs in systemic lupus erythematosus: progress and prospects","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2019.03.006_bib1085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phrs.2015.03.010","article-title":"Glycogen synthase kinase-3 beta (GSK-3\u03b2) signaling: Implications for Parkinson's disease","volume":"97","author":"Golpich","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2019.03.006_bib1090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2018.10.030","article-title":"Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases","volume":"161","author":"Nozal","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.03.006_bib1095","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: justum pretium \u2013 the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib1100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2017.07.004","article-title":"Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care","volume":"55","author":"Yezefski","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.phrs.2019.03.006_bib1105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2019.03.006_bib1110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.03.006_bib1115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819304256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819304256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:57:07Z","timestamp":1760911027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819304256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":223,"alternative-id":["S1043661819304256"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.006","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule protein kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}